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Abstract 
The regeneration of large bone defects remains clinically challenging. The aim of our study 
was to use a rat model to use nasal chondrocytes to engineer a hypertrophic cartilage tissue 
which could be remodelled into bone in vivo by endochondral ossification.   
Primary adult rat nasal chondrocytes were isolated from the nasal septum, the cell numbers 
expanded in monolayer culture and the cells cultured in vitro on polyglycolic acid scaffolds 
in chondrogenic medium for culture periods of 5-10 weeks. Hypertrophic differentiation was 
assessed by determining the temporal expression of key marker genes and proteins involved 
in hypertrophic cartilage formation. The temporal changes in the genes measured reflected 
the temporal changes observed in the growth plate. Collagen II gene expression increased 6 
fold by day 7 and was then significantly downregulated from day 14 onwards. Conversely, 
collagen X gene expression was detectable by day 14 and increased 100-fold by day 35. The 
temporal increase in collagen X expression was mirrored by increases in alkaline phosphatase 
gene expression which also was detectable by day 14 with a 30-fold increase in gene 
expression by day 35.  Histological and immunohistochemical analysis of the engineered 
constructs showed increased chondrocyte cell volume (31-45 µm), deposition of collagen X 
in the extracellular matrix and expression of alkaline phosphatase activity. However, no 
cartilage mineralisation was observed in in vitro culture of up to 10 weeks. On subcutaneous 
implantation of the hypertrophic engineered constructs, the grafts became vascularised, 
cartilage mineralisation occurred and loss of the proteoglycan in the matrix was observed. 
Implantation of the hypertrophic engineered constructs into a rat cranial defect resulted in 
angiogenesis, mineralisation and remodelling of the cartilage tissue into bone. Micro-CT 
analysis indicated that defects which received the engineered hypertrophic constructs showed 
38.48% in bone volume compared to 7.01% in the control defects. 
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Development of tissue engineered hypertrophic cartilage to use as a bone graft substitute is 
exciting development in regenerative medicine. This is a proof of principal study 
demonstrating the potential of nasal chondrocytes to engineer hypertrophic cartilage which 
will remodel into bone on in vivo transplantation. This approach to making engineered 
hypertrophic cartilage grafts could form the basis of a new potential future clinical treatment 
for maxillofacial reconstruction.  
1. Introduction 
Bone is the second most transplanted tissue after blood. Despite this, the repair of large bone 
defects, whether congenital in nature or caused by trauma or disease remains clinically 
challenging. [1] Crucially, survival of transplanted bone tissue into a bone defect is 
dependent on the tissue receiving adequate blood supply to supply essential oxygen and 
nutrients and removal of waste products. Currently, autologous bone is the clinical µgold 
standard¶ for bone tissue transplantation. Autologous bone is a living tissue with 
RVWHRFRQGXFWLYH DQG RVWHRLQGXFWLYH SURSHUWLHV ZKLFK ZLOO QRW EH UHMHFWHG E\ WKH SDWLHQW¶V
immune system. There are, however, drawbacks to using autologous bone tissue including 
lasting post-operative pain from the donor site and donor site morbidity. [2] There are also 
limitations in the amount of healthy tissue that can be taken from a patient without causing 
instability in the remaining bone structures, an issue particularly pertinent in children. [2] 
Bone allografts and xenografts are used for bone repair, but these have to be decellularised to 
reduce their immunogenicity and as a consequence, are osteoconductive but have little 
osteoinductive capacity. Similarly, to date, current biomaterial bone graft substitutes have 
good osteoconductive properties but their osteoinductive properties are limited. Therefore, 
there is a strong clinical need to develop new bone graft materials for the repair and 
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regeneration of bone defects. Tissue engineering and regenerative medicine technologies are 
SURPLVLQJµWRROV¶WRJHQHUDWHERQHJUDIWsubstitutes to fill this demand.  
Most tissue engineering approaches have focussed on producing bone tissue by the route of 
intramembranous ossification in which mesenchymal stem cells are differentiated directly 
into osteoblastic cells to produce a bone-like extracellular matrix directly. One of the main 
challenges of bone tissue engineering by this route is the provision of a sufficient supply of 
nutrients and oxygen essential for the survival of the osteoblastic cells. During the culture of 
large three-dimensional tissue constructs, limited diffusion can cause problems in cell 
proliferation, differentiation and cell survival. Approaches to overcome these limitations 
include use of bioreactors [3,4] to provide dynamic culture conditions and engineering pre-
vascularised grafts by including endothelial cells with differentiation signals to stimulate 
formation of blood capillaries [5]. 
Developmental tissue engineering, mimicking the natural pathways of tissue formation in 
body is a potential route to producing graft tissues for transplantation. Endochondral 
ossification is responsible for the formation of the axial skeleton and long bones [6] during 
embryogenesis and, is a potential and as of yet largely unexplored pathway of producing a 
suitable, alternative graft material for bone repair. Endochondral ossification involves the 
formation of a hypertrophic cartilage template which undergoes mineralisation, invasion by 
blood vessels and subsequent remodelling into bone. Hypertrophic cartilage formation and its 
remodelling into bone by endochondral ossification can be seen in the growth plate of young 
children and adolescents during periods of active growth and in the adult during healing of 
bone fractures where the µsoft¶ cartilage callus undergoes ossification into woven bone. In the 
growth plate, proliferative columnar chondrocytes produce a complex hyaline-cartilage 
extracellular matrix (ECM), in which the predominant protein is collagen type II. These 
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chondrocytes then undergo terminal differentiation to the hypertrophic chondrocyte 
phenotype and produce collagen type X in the ECM which is essential for mineralisation [7, 
8].  
Cartilage constructs have several advantages over the more extensively researched bone 
tissue constructs formed by intramembranous ossification. Cartilage can withstand lower 
oxygen concentrations than bone tissue containing osteoblasts and mesenchymal stem cells 
[9]. This advantage of cartilage allows for both the culture of larger grafts, as well as enabling 
better survival of the cartilage graft once implanted at the site of injury. Hypertrophic 
cartilage also contains the required biological factors to promote matrix remodelling [10], 
angiogenesis [11, 12], and bone formation [13], within the tissue. Therefore, once implanted 
in vivo, hypertrophic cartilage should recruit blood vessels and be remodelled into bone tissue 
via the normal physiological process of endochondral ossification. Hence, the potential of 
utilising tissue engineered hypertrophic cartilage warrants further research. 
There has been widespread interest in the use of mesenchymal stem cells in regenerative 
medicine and tissue engineering for repair/regeneration of hyaline cartilage defects in the 
body; for example regeneration of articular cartilage in joints [14, 15] and cartilage defects in 
the head and neck area [16] for example, the nasal septum [17, 18]. In comparison, there has 
been little research focussed on engineering hypertrophic cartilage. Scotti et al demonstrated 
that bone marrow mesenchymal stem cells (BM-MSCs) in pellet culture were able to 
differentiate into hypertrophic-like chondrocytes which expressed both collagen type X and 
alkaline phosphatase and mineralised on subcutaneous implantation [7]. Scotti et al also 
reported that seeding BM-MSCs on a shaped collagen scaffold followed by chondrogenic 
priming formed a mineralised trabecular-like bone on subcutaneous implantation [19]. 
Sheehy et al [20] have also recently reported that BM-MSCs encapsulated in a shaped 
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hydrogel structure formed layer of mineralised tissue in the periphery of the constructs after 
in vitro chondrogenic priming followed by 8weeks of subcutaneous implantation. While 
mesenchymal stem cells have been approved for clinical use [21] other adult cells may offer 
an advantageous source for the production of a hypertrophic cartilage. Mesenchymal stem 
cells have been shown to produce cartilage with lower levels of ECM and reduced 
mechanical strengths when compared to adult chondrocytes [22, 23]. Primary adult hyaline 
chondrocytes, however, have been shown to produce high levels of GAG in the ECM when 
cultured in vitro, for the production of hyaline cartilage [22, 24].   
In terms of using chondrocytes to form hypertrophic cartilage, previous research has shown 
that immortalised adult articular chondrocytes become hypertrophic and mineralised in pellet 
culture [25]. Also, immortalised chondrocytes derived human embryonic femurs were 
reported to produce osteoinductive signals in the culture medium [26]. There are, however, 
significant regulatory and safety concerns associated with the use of genetically modified 
cells for clinical applications. Two sources of adult chondrocytes, nasal septum and rib 
cartilage, have potential as sources of adult hyaline chondrocytes which can undergo terminal 
differentiation to the hypertrophic phenotype. Both tissues have capacity in vivo for the 
cartilage to undergo endochondral ossification; for example, where the nasal cartilage is 
attached to the facial bone. Also, both tissues can be harvested clinically by biopsy. The nasal 
septum is potentially a simpler biopsy procedure with a lower risk of donor site morbidity. In 
addition, chondrocytes extracted from the nasal septum have been broadly studied in tissue 
engineering for their capacity to produce a hyaline cartilage matrix [24, 27-29] and have been 
used clinically for repair of septal defects [17]. Only one detailed in vivo study to date has 
considered the use of nasal chondrocytes for tissue engineering a hypertrophic cartilage 
template for bone regeneration [30]. Here engineered constructs did not mineralise following 
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sub-cutaneous implantation, but were capable of some mineralisation following osteogenic 
pre-culture and implantation within ceramic scaffolds. More recently, a population of 
nasoseptal chondrocytes with progenitor features were described by Rotter and co-workers 
[31]. 
The overall aim of this study was to investigate whether chondrocytes isolated from the nasal 
septum, a potentially clinically relevant cell source, could produce a hypertrophic cartilage 
tissue which would remodel into bone on transplantation into a bone defect in vivo. Our first 
objective was to use a rat model in which to isolate and culture nasal chondrocytes and 
investigate whether the chondrocytes would produce a hypertrophic cartilage matrix in 3D 
culture using a poly-L-glycolic acid (PGA) scaffold support. Chondrocytes were also isolated 
from the rib and cultured in the same way as a comparator. The second objective was to 
implant the engineered hypertrophic cartilage subcutaneously in vivo to investigate 
biocompatibility, and angiogenesis in the implant. The engineered hypertrophic cartilage was 
also implanted in an in vivo bone defect in the calvaria of the rat to determine whether the 
cartilage would undergo remodelling into bone.  
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2. Materials and methods 
2.1 Cell Isolation and Expansion 
Nasal and rib cartilages were harvested from 6 week old Wistar rats within 2 hours of 
euthanasia and the chondrocytes isolated and cultured as we have described previously [32, 
33] and is a similar method of cell isolation and expansion as reported by other researchers 
[24, 29, 31,] Briefly the cartilages were removed, washed in phosphate buffered saline (PBS) 
and any epithelial tissue removed by scraping the cartilage surfaces with a scalpel blade. The 
cartilages were again washed with PBS, cut into small pieces and  incubated in 2.5% trypsin 
(Sigma Aldrich, UK) for 30 minutes followed by an overnight digestion in 3 mg.ml-1 
bacterial collagenase Sigma Aldrich, UK) in basic medium [DXOEHFFR¶V PRGLILHG HDJOH
medium (DMEM) (Sigma Aldrich, UK) supplemented with non-essential amino acids 
(NEAA) (Sigma Aldrich, UK), 100 units.ml-1 penicillin and 100 ug.ml-1 streptomycin (Sigma 
Aldrich, UK), and 10 mM HEPES buffer (Sigma Aldrich, UK) and  10 % foetal calf serum 
(FCS, Biosera, UK)]. The chondrocytes were isolated from the digested tissue by passing the 
digested tissue through a 70 µm cell strainer (BD Biosciences, UK) followed by 
centrifugation (10 min, 192g) to pellet the cells. The cell pellet was washed to remove by 
suspending the cells in PBS and repeating the centrifugation step. This washing step was 
repeated once more and the final cell pellet suspended in basic culture medium containing 10 
ng.ml-1 of fibroblast growth factor-2 (FGF-2, Peprotech, UK). The cells were plated into 
culture flasks and cultured in an incubator at 37oC a humidified atmosphere of 5% CO2 and 
95% air. The culture media (basic medium containg10 ng.ml-1 FGF-2) was changed twice per 
week. 
 
2.2 Scaffold 
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A commercial PGA scaffold (Biofelt®, Cellon S.A., Luxembourg) was used. The Biofelt® 
scaffold was a biodegradable, 1 mm thick, non-woven PGA felt with a bulk density of 
70mg.cc-1 and was fabricated from medical grade polymer. For experiments, 5 mm diameter 
discs were cut from the scaffold sheet using a cork borer and the discs were covered with 
isopropanol for 15 min. to sterilise them, a method recommended by the manufacturer. The 
isopropanol was removed and the discs washed extensively with sterile PBS to ensure 
removal of the isopropanol. The scaffold discs were then conditioned in basic media for a 
further 20 minutes.  This scaffold has been reported extensively, primarily as a reference 
material in investigations of novel biomaterials [34-36]. 
 
2.3 Scaffold Seeding and 3D Culture 
At passage 2, 2x106 cells were seeded per PGA scaffold for 72 hours in basic medium on an 
orbital shaker set at 35 revolutions per minute (rpm). The seeded constructs were removed 
and placed in fresh culture medium and then cultured for 42 days in basic medium containing 
1 µg.ml-1 insulin and 50 µg.ml-1 ascorbic acid, to induce chondrocyte differentiation and 
extracellular matrix formation. After culture, the constructs were removed from the culture 
wells, lightly blotted with tissue to remove excess medium and weighed. The constructs were 
bisected perpendicularly and for each construct, one half was frozen at -20 oC for analysis of 
GAG content and the remaining half was mounted in Optimal Cutting Temperature (OCT) 
cyromountant and stored at -20 ºC for histology and immunohistochemistry. 
 
2.4 Glycosaminoglycan assay 
Freeze dried constructs were digested overnight at 60 oC in 200 mM phosphate buffer, pH 
6.8, containing 1 mM EDTA, 6 mM n-acetyl cysteine and 0.05 % (w/v) papain (from papaya 
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latex, Sigma Aldrich UK) After digestion, the samples were centrifuged at 10,000g to pellet 
remains of the PGA scaffold and the supernatant fraction was removed and stored at -20oC 
until assay for glycosaminoglycan (GAG) content, The GAG concentration of the digested 
samples was determined using 1,9-dimethylmethylene blue (DMB) following the protocol 
described by Farndale et al. [37].  
2.5 Histology 
 ȝP frozen sections were taken from OCT-mounted constructs and transferred to 3-
aminopropyltriethoxysilane (APES) coated slides. Sections were fixed in paraformaldehyde 
and stained using Haematoxylin and Eosin (Sigma Aldrich, UK), to determine general tissue 
morphology. Sections were also stained for extracellular matrix GAGs using Alcian Blue [1 
% (w/v) Alcian Blue in 3% acetic acid pH 2.5, (Sigma Aldrich, UK)] and counterstained with 
a 0.5 % (w/v) aqueous solution of Neutral Red (Sigma Aldrich, UK), or 1% (w/v) Toluidine 
Blue in 0.5 % (w/v) sodium borate, (Sigma Aldrich, UK). Mineral deposition was determined 
by staining construct sections with 1.4 % Alizarin Red aqueous solution pH 4.1, (Sigma 
Aldrich, UK). Distribution of alkaline phosphatase was assessed in the construct sections 
using SIGMAFASTTM BCIP®/NBT (5-bromo-4-chloro-3-indoyl phosphate/ Nitro blue 
tetrazolium, Sigma Aldrich, UK) DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV 
 
2.6 Immunohistochemistry 
Immunohistochemistry was used to assess collagen type II and X deposition throughout the 
constructs. Collagen expression was investigated using commercial antibodies: goat anti-
collagen type II antibody (dilution 1:20 Cambridge Bioscience, UK) and mouse anti-collagen 
type X antibody (dilution 1:100, Quartet, Berlin, Germany). Detection was carried out with 
complementary secondary biotinylated antibodies (Vectastain ABC kit, Vector Laboratories 
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Ltd, UK) and visualization performed with diaminobenzidine tetra hydrochloride (DAB) 
substrate (9HFWRU/DERUDWRULHV/WG8.7KHFHOOQXFOHLZHUH FRXQWHUVWDLQHGZLWK0D\HU¶V
Haematoxylin (Sigma Aldrich, UK). Supplementary Figure 1 shows in detail the low level of 
non-specific staining obtained using the antibodies.  Images showing the level of non-specific 
staining in each experiment are shown as inserted images in the immunohistochemical 
images. 
  
2.7 Real Time RT-PCR (q-PCR) 
After culture, the constructs were washed in PBS and flash frozen in liquid nitrogen for 30 
seconds. A tissue pulveriser was used for 1 minute to homogenise the sample in PBS and the 
samples centrifuged at 11,000 rpm for 2 minutes. RNA was extracted immediately from the 
tissue pellet using a Bioline Isolate II RNA Mini Kit (Bioline Reagents Ltd, UK) and the 
concentration determined using a Nanodrop 2000. cDNA was synthesised using a high 
capacity RNA to cDNA master mix (Life Technologies, UK) and 100 ng of RNA per 
reaction. Reactions were run in a thermal cycler using a cycle of 10 minutes at 25 °C, 2 hours 
at 37 °C, 5 minutes at 85 °C and then 10 minutes at 4 °C.  
Real time PCR was performed using a 7900 Fast Real Time PCR machine in a 96-well plate 
with an experimental volume of 10 µl. Taqman probes and primers (Life Technologies, UK) 
were used for the detection of the expression of collagen type II, alpha 1 (Rn01637087_m1), 
collagen type X, alpha 1 (Rn01408030_m1), alkaline phosphatase (Rn00575319_g1), indian 
hedgehog (IHH) (Rn03810376_m1), SRY (sex determining region Y)-box 9 (Sox9) 
(Rn01751069_mH) and runt-related transcription factor 2 (Runx2) (Rn01512298_m1). Non 
template and reverse transcriptase negative controls were used to check for cDNA 
contamination.  
13 
 
Results were analysed XVLQJ WKH ǻǻFW PHWKRG LQ UHODWLRQ WR WKH KRXVHNHHSLQJ JHQH
glyceraldehyde 3-phosphate dehydrogenase *$3'+ ( H[SUHVVLRQ 7KH ǻǻFW
value was then normalised to undifferentiated 3D culture chondrocytes, to assess the 
differentiation on the PGA scaffold material. 
2.8 In vivo Experiments 
2.8.1. Subcutaneous implantation of constructs. 
Rat nasal chondrocytes were cultured on PGA scaffolds under standard conditions as 
described above. The scaffolds were cultured in vitro for 42 days. This time period was used 
to enable the culture expanded cells to regain their chondrogenic phenotype and maximise 
expression of hypertrophic features (as indicated by the in vitro qPCR, histological and 
immunohistochemical data). At day 42 several PGA constructs were cryopreserved in OCT. 
This group formed the 6-week in vitro control to enable determination of the stage of 
chondrocyte differentiation prior to implantation. The remaining constructs were either 
implanted subcutaneously for 4 weeks (1 hypertrophic construct per animal plus 1 cell-
free/empty scaffold control) or left for a further period of 4 weeks in in vitro culture to match 
the time period of the in vivo implantation. This latter group formed the 10-week in vitro 
control to investigate any further changes which would occur on extending the in vitro culture 
period for a further 4 weeks. All experiments were carried out under the appropriate Home 
Office regulatory licence (Licence number 40/2795). 12-week old Wistar rats (n=4) were 
kept under conventional housing conditions with free access to food and water. The 
constructs and empty scaffolds were placed in subcutaneous pockets on the backs of 
anaesthetised animals. After 4 weeks, the rats were sacrificed and the constructs retrieved. 
Cell-free/empty scaffolds could not be retrieved after 4 weeks of implantation as they had 
completely dissolved. 
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2.8.2. Insertion of constructs into a cranial defect in the rat. 
Constructs were cultured in vitro for 35 days to enable the culture expanded cells to regain 
their chondrogenic phenotype and gain hypertrophic features after which, they were washed 
in PBS prior to implantation into the cranial bone defects. The constructs were placed in 4 
mm full thickness healing defects in the calvaria of 8-week old Wistar rats. All in vivo 
experiments were performed under the appropriate Home Office animal license (license 
number: 40/3311). 
Rats were anaesthetised using IsoFlo (Isofluorane, Abbott Laboratories, UK) and given 
antibiotics, Synulox (Pfizer, UK), and a painkiller, Metacam (Boehringer-Ingleheim, 
Germany). The anesthetised animals were weighed and a midline incision was made in the 
skin covering the skull and both the skin and periosteum were retracted to reveal the cranium. 
Two 4 mm full thickness defects were drilled into the skull using a 3.5 mm diamond burr 
with saline irrigation. The constructs Grafts were cut to 4 mm diameter using a sterile biopsy 
punch and placed into one of the defects with the other being left empty. The periosteum was 
closed over the defects and secured with 2 vicryl stitches, before the wound was closed using 
4-5 stitches.  
Constructs were left in the cranial defects for 4, 8 or 12 weeks, before the animals were 
culled. Rats were anesthetised using IsoFlo and their vertebrae separated, the heads were then 
removed from the animal and placed in 10 % (w/v) neutral buffered formalin. The cranial 
defects were then examined by microcomputed tomography (micro-CT) and histology to 
assess the degree of new bone formation in the defect area. 
The skulls were analysed using a desktop high resolution micro-CT system (Skyscan 1172, 
Skyscan, Belgium). Scans were performed at 100 kVp, with a 1 mm aluminium filter and a 
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SL[HOVL]HRIȝP,PDJHVZHUHWDNHQWKURXJKRXWZLWKLPDJHVEHLQJDYHUDJHGDW
each point.  
After micro-CT analysis the soft tissue was removed and the skulls decalcified by incubation 
in an aqueous solution of 0.5 M EDTA and 0.4 M sodium hydroxide in pH 7.0 for 14 days. 
After decalcification the craniums were dissected and embedded in paraffin wax for 
histological analysis. 
 
3. Results  
3.1 Analysis of Constructs 
Sternal and nasal hyaline chondrocytes were compared for their ability to undergo 
hypertrophic differentiation on PGA scaffolds. Both sternal and nasal-derived chondrocytes 
seeded onto the scaffolds to a similar extent (over 90% seeding efficiency). The constructs 
were incubated for up to 42 days after which they were terminated and analysed as described 
in the methods. Deposition of proteoglycan, collagens II and X showed extensive distribution 
in constructs formed from either nasal or sternal chondrocytes by day 42 (Figure 1). An 
increase in cell volume was found in constructs from both chondrocyte types and collagen X 
deposition was observed in areas of chondrocytes showing increased cell volume. (Figure 1) 
Quantification of the ECM deposition was assessed by determining the amount of 
proteoglycan deposition by measuring the levels of GAGs (expressed as a percentage of the 
dry weight of the construct ECM). The percentage of GAGs increased in the ECM with the 
duration of culture and reached similar levels in constructs of nasal chondrocytes (28.75% ± 
1.25) and sternal chondrocytes (30.0% ±1.25) by day 42. Alkaline phosphatase activity was 
widely distributed throughout constructs of nasal chondrocytes (Figure 1b, presence of 
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alkaline phosphatase activity shown by back/brown staining). In contrast, little alkaline 
phosphatase activity was detected in constructs from sternal chondrocytes (Figure 1a) 
indicating a full hypertrophic chondrocyte phenotype in the sternal chondrocytes was not 
achieved under the incubation conditions used. Therefore, constructs formed from nasal 
chondrocytes had the capacity to express features of hypertrophic chondrocytes and were 
used to further investigate the hypertrophic phenotype and determine whether they could be 
remodelled into bone tissue in vivo 
Figure 1: Representative histological and immunohistochemical staining of tissue sections of 
constructs of sternal (a) or nasal chondrocytes (b) seeded on PGA scaffolds and cultured for 
42 days. The legend above the images show the staining procedures used. Images show 
histochemical staining by Haemotoxylin and Eosin (H&E) to show general tissue 
morphology, distribution of proteoglycan (shown by Alcian Blue staining, proteoglycans 
stained blue), localisation of collagen II and collagen X (collagen localisation shown by 
brown staining) and histochemical staining for alkaline phosphatase activity (ALP, enzyme 
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activity shown by black/brown stained). Control sections showing non-specific antibody 
staining are inserted into the immunohistochemical images. Scale bars = 200 µm.  
 
Significant morphological and phenotypical changes were observed within constructs of nasal 
chondrocyte throughout the 42-day culture period (Figure 2a). After seeding of the constructs 
and during the early culture period, the nasal chondrocytes exhibited a cell size and 
morphology equivalent to that of a hyaline chondrocyte phenotype (8-12 µm, day 14). By day 
28 of culture, chondrocytes with an increased cellular size (31-45 µm), indicative of a 
hypertrophic phenotype, were observed in isolated pockets of the constructs. By day 42 of 
culture, the constructs showed a uniform distribution of hypertrophic-like chondrocytes. 
Regarding extracellular matrix (ECM) formation, little deposition (in terms of collagen II and 
proteoglycan) was observed by day 14 in the constructs. However, the ECM deposition 
increased with the length of incubation as shown by the increasing tissue morphology at days 
28 and 42 and localisation and increasing deposition of proteoglycans within the constructs, 
as shown by quantitative determination of GAGs (a measure of proteoglycan) in the 
constructs (Figure 2b). Expression of the major cartilage proteins within the ECM was also 
altered throughout the culture period and indicative of hypertrophic differentiation. The 
constructs showed expression of collagen type II by day 14 with no detectable expression of 
collagen type X. By day 28, collagen X was detected in the constructs in areas showing 
hypertrophic chondrocytes. However, little alkaline phosphatase activity was observed at this 
time point. By day 42, both collagen X and alkaline phosphatase localisation were observed 
along with most cells showing a hypertrophic morphology (Figure 2a). The degree of 
mineralisation of the construct was assessed at day 42 and while the constructs showed 
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hypertrophic differentiation in terms of alkaline phosphatase and collagen X protein 
deposition, no mineralisation was detected during the in vitro culture period. 
Figure 2: (a). Representative histological and immunohistochemical staining of tissue 
sections from nasal chondrocytes seeded on PGA scaffolds and cultured for 14, 28 and 42 
days. The images show immunolocalisation of collagens II and X and alkaline phosphatase 
activity. Collagen II was detectable from day 14. By day 28, the chondrocytes exhibited an 
increased cell size and collagen X was detected with an extensive distribution of collagen X 
by day 42. Alkaline phosphatase activity was also detectable at days 28 and 42. Calcium 
deposition was investigated using Alizarin Red after 42 days of incubation; however, no 
calcium deposition was observed. (b). Shows the glycosaminoglycan (GAG) accumulation 
(expressed as a % of the tissue dry weight) in the nasal chondrocyte constructs with time of in 
vitro culture. During the 42 day culture period the amount of GAG in the constructs 
increased, indicating increased extracellular matrix deposition throughout the incubation 
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period. (n=6, errors plotted as standard error of the means, * p<0.05). Scale bars=100µm. 
Control sections showing non-specific antibody staining are inserted into the 
immunohistochemical images. 
 
3.2 Effect of 3D Culture on Chondrocyte Gene Expression 
After isolation from native cartilage, the nasal chondrocytes were grown in 2-dimensional 
(2D) monolayer culture to expand the numbers of cells. After culturing the chondrocytes on 
the PGA scaffold for 72 hours in basal media a distinct change in the gene expression was 
observed (Supplementary data, Figure 2) compared to the 2D monolayer cultures. Significant 
increases in the expression of Ihh, Sox9, and collagen type II were observed indicating the 
chondrocytes were reverting to a more hyaline phenotype. Conversely markers of 
hypertrophic differentiation, collagen type X, alkaline phosphatase and Runx2, were 
significantly decreased during the first 72h of culturing the chondrocytes were in the 3D 
environment of the PGA scaffolds.  
3.3 Effect of Differentiation on Chondrocyte Gene Expression 
Gene expression within the cartilage constructs changed significantly throughout the 42-day 
culture period following the scaffold seeding period (Figure 3). The ECM component, 
collagen II, a marker of a hyaline chondrocyte phenotype, continued to increase after the 
initial 72 hour cell- seeding period, until day 7 where a 6-fold increase in gene expression 
was observed. After day 7, the gene expression of collagen II was significantly 
downregulated throughout the remainder of the culture period (Figure 3a). Conversely, gene 
expression for collagen X increased from day 7 to day 14 with a reproducible decease in 
expression at day 21 followed by increase expression to reach a peak of 100-fold increase at 
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day 35 (Figure 3b). Similarly, gene expression for alkaline phosphatase increased from day 7 
to peak levels by days 35 (Figure 3c). The gene expression of the signalling protein, Indian 
hedgehog (IHH), a pre-hypertrophic marker, rose from day 14 with a significant peak in 
expression by day 21 (30-fold increase) before falling to lower levels (6 fold) (Figure3d). 
Gene expression of the transcription factor Sox9 was significantly reduced at day 3 until day 
35 when there was an increase in expression corresponding with the timing of peaks in 
collagen type X and alkaline phosphatase gene expression (Figure 3e). Expression of the 
transcription factor, Runx2 was increased by day 14 of the culture period and reached a peak 
in gene expression by day 28. Gene expression of Runx2 then deceased to around 3-fold 
increase at day 35 (Figure 3f).  
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Figure 3: mRNA expression of genes associated with endochondral ossification during 
hypertrophic differentiation. Data was normalised to gene expression observed after the 72-
hour period of cell seeding of the scaffold. (a) collagen type II &ROĮFKDLQ; (b) collagen 
type X &RO;ĮFKDLQ); (c) alkaline phosphatase; (d) Indian hedgehog (IHH); (e) SRY (sex 
determining region Y)-box 9 (SOX9) and (f) runt-related transcription factor 2 (Runx2).   (* 
p<0.05), ** p<0.01 and *** p<0.001. n = 4)   
3.5 In Vivo Repair 
Subcutaneous implantation 
Since the hypertrophic constructs failed to mineralise in vitro; subcutaneous implantation of 
the hypertrophic constructs was carried out to determine if the constructs would undergo 
mineralisation in vivo. Before implantation, the constructs showed features of hypertrophic 
cartilage tissue shown by areas of hypertrophic cells; some areas of collagen X deposition in 
the ECM and alkaline phosphatase enzyme activity (refer to Supplementary Figure 3). 
Histological analysis of the retrieved constructs revealed that they were encapsulated by a 
thin layer of fibrous, connective tissue.  Immunolocalisation studies, using anti-CD45+ to 
detect leukocytes and anti-CD68+ antibodies to detect macrophages, showed some 
inflammatory cells were present around the outer areas of the retrieved constructs but their 
localisation was sparse and was restricted mostly to non-cartilage areas (Supplementary 
Figure 4). No giant cells were detected. 
Numerous blood vessels were present on the surface of implants and throughout their interior 
after 4 weeks of implantation (Figure 4b, g). Tissue remodelling was observed in regions 
adjacent to connective tissue in the periphery of the cartilage construct and around areas 
invaded with blood vessels (Figure 4g) cartilage matrix remodelling is clearly visible on 
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sections stained with Alcian Blue and Eosin where single chondrocytes, were still embedded 
in a thin layer of GAGs, are surrounded by newly formed non-cartilaginous matrix (Figure 
4g). After 4 weeks of implantation collagen X was distributed throughout the cartilaginous 
areas of constructs (Figure 4a, b). Additionally, alkaline phosphatase was detected in the 
implanted constructs (Figure 4c, d). In contrast to the in vitro experiments, after 4 weeks of 
implantation calcium deposition was observed in all the samples (Figure 4e, f) Mineralised 
matrix was found in cartilaginous areas around the chondrocytes and it was largely co-
localised with areas of high alkaline phosphatase activity. However histologically, the 
mineralisation appeared to be due to mineralised cartilage as no apparent bone formation was 
observed in these experiments.   
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  Figure 4: Representative histological and immunochemical sections of the retrieved 
constructs after 4 weeks of subcutaneous implantation.  The images show distribution of 
collagen X (a, b), alkaline phosphatase (c, d), calcium deposition in  Alizarin Red stained 
images e to g) and decreased staining for glycosaminoglycans from the areas invaded by 
blood vessels (Alcian Blue/Eosin stained section, h). Scale bars = 500 µm (a, c, e) 100 µm 
(b, d, f, h) and 50 µm (g). 
In contrast, no mineralisation was observed in the constructs which were maintained in in 
vitro culture for an additional period of 4 weeks (Supplementary Figure 5) although extensive 
deposition of collagen X and alkaline phosphatase activity was observed during the extended 
culture period. 
 
Cranial implantation 
The pre-implantation constructs after 35 days of differentiation showed a hypertrophic 
phenotype in terms of large cell size, collagen X and alkaline phosphatase expression 
(Supplementary Figure 6).   
In the absence of cells and some ECM formation, PGA has a very rapid rate of dissolution 
releasing acidic degradation products which had the possibility of causing an inflammatory 
reaction in a relatively confined area close to the surface of the brain [39]. Therefore, a cell-
free PGA scaffold could not be implanted into the empty defect. Implantation of a tissue 
engineered hypertrophic cartilage graft promoted bone mineralised formation at all time 
points examined (Figures 5a, 5b, 5c). After 4 weeks the hypertrophic graft gave 15.15 % 
mineralisation within the defect compared to 7.06 % in the untreated defects. Histological 
analysis indicated the initiation of vascularisation within the graft as well as a decrease in 
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GAG around the invading blood vessels by 4 weeks). At 8 weeks a significant increase was 
observed in the percentage bone volume of the treated defects compared to the untreated 
defect (22.94 % and 7.07 % respectively) (Figures 5b and 5d). This is also supported by the 
morphological appearance of the bone-like tissue which has formed within the defect when 
analysed histologically (Figure 6 a, b). By week 12, micro-CT data showed that 38.48 % of 
the defect was mineralised (Figures 5c, d) compared to the untreated defect (7.56%) and 
further remodelling of the hypertrophic cartilage into bone was also observed histologically. 
Little bone formation was observed within the calvarial defects which had remained empty 
(i.e. they had not received a hypertrophic cartilage construct). In these a fibrous tissue had 
formed bridging the defect (Supplementary Figure 7). 
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Figure 5: Micro-CT analysis of defects. (a ± c) Micro-CT images showing the mineralisation 
within a 4 mm cranial defect either left empty with no graft material implanted or treated with 
a hypertrophic cartilage graft after implantation periods of (a) 4 weeks; (b) 8 weeks and (c) 
12 weeks.  Figure 5d shows the volume of bone ingrowth determined by micro-CT within the 
defects throughout the healing period. (* p<0.05, ** p<0.01, n=3). 
 
 
Figure 6: Representative images of the haematoxylin and eosin staining of decalcified 
sections of cranial defects treated with a hypertrophic cartilage graft after 8 weeks of in vivo 
implantation. Images show infiltration by blood vessels and formation of bone-like tissue 
around the areas of blood vessel infiltration. Total magnification: image (a) x40, image (b) 
x200. 
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4. Discussion 
This is a proof of concept study using a rat model which shows the use of nasal chondrocytes 
to produce a tissue engineered hypertrophic construct in vitro. This study has demonstrated 
that this engineered hypertrophic cartilage material has the ability to undergo ossification and 
enhance bone regeneration in a bone defect in vivo.  Non-woven PGA was chosen as a 
scaffold material as these polyesters have been well researched for tissue-engineering as they 
have Food and Drug Administration approval for clinical use [38]. PGA has the disadvantage 
of releasing glycolic acid by-products during degradation, and has been reported to induce 
inflammation and necrosis of nearby tissues [39]. Use of a PGA scaffold allowed for good 
cell attachment, proliferation and hypertrophic differentiation. On subcutaneous implantation 
of the hypertrophic constructs, a mild inflammatory response was observed on the periphery 
of the construct indicated by immunolocalisation of macrophages (CD 45+ cells) and 
lymphocytes (CD68+cells).  No obvious inflammation was observed on implantation of the 
hypertrophic constructs into the cranial bone defect model.    
The tissue engineered hypertrophic cartilage produced in this study was shown to have 
similar features to that seen in the growth plate. The engineered tissue exhibited a large 
cellular morphology and expressed the classical hypertrophic cartilage markers of collagen 
type X and alkaline phosphatase in the extracellular matrix. The temporal gene expression of 
Sox9, collagens II and X, Runx2 and alkaline phosphatase during the in vitro culture period 
in the nasal chondrocyte/PGA constructs also reflected that observed during chondrocyte 
hypertrophy within the growth plate [41]. Chondrocytes are well known to dedifferentiate 
during 2D culture conditions which are used to expand the numbers of cells for seeding onto 
scaffolds [40]. During 3D culture, the gene expression of collagen II was elevated by day 7 
and  indicative of the chondrocytes regaining a hyaline chondrogenic phenotype. By day 14 
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the collagen II gene expression was significantly down regulated and collagen X expression 
increased with alkaline phosphatase gene expression from day 7 of the culture reaching a 
peak at day 35 of culture. The temporal gene expression of signalling molecule, IHH, and 
transcription factors, Sox9 and Runx2 were also monitored throughout the differentiation 
period and found to reflect that reported for chondrocyte hypertrophy in the growth plate.  
In the growth plate, IHH expression is localised to the area of post-mitotic, pre-hypertrophic 
chondrocytes which is adjacent to the proliferating columnar cells and regulates hypertrophic 
differentiation of chondrocytes [42]. IHH is reported to work through two mechanisms, 
inhibiting hypertrophic differentiation through the PTHrP pathway and Ptc-1 receptor or 
promoting hypertrophic differentiation through the Wnt/BMP pathway [42-45]. A peak of 
IHH gene expression was observed at day 21 just before a peak of Runx2 expression. Runx2 
is essential during hypertrophic differentiation as it is known to regulate the expression of 
other genes associated with mineralisation and angiogenesis, including BMPs and VEGF to 
induce angiogenesis in the cartilage. Runx2 also promotes the extracellular matrix 
remodelling via synthesis of matrix metalloproteinases (MMPs) and osteopontin which 
enables osteoclast attachment [48-52]. These downstream proteins are essential for the 
subsequent mineralisation and bone formation within the tissue-engineered hypertrophic 
cartilage.  Sox9 is believed to work via the PTHrP pathway to maintain cells in a proliferative 
state. [46]. Dy et al, however, have shown that Sox9 is also an important transcription factor 
for hypertrophic differentiation, where it is located to the nuclei of chondrocytes where it acts 
upon the collagen type X promoter both independently and through cooperation with mef2c 
[47]. We observed downregulation of Sox9 throughout the culture period with increased 
Sox9 expression on day 35 which corresponded to the peak expression of collagen type X 
within the constructs.  
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This ability to create an engineered tissue with the morphological and phenotypical feature of 
natural hypertrophic cartilage is essential to allow of mineralisation and bone remodelling in 
vivo. While the production of an engineered tissue with characteristics of hypertrophic 
cartilage was successful in vitro on the PGA scaffold material, these constructs failed to show 
cartilage mineralisation in vitro. However, the constructs did undergo cartilage mineralisation 
on in vivo implantation (Figure 4) but not on extended in vitro culture. Mineralisation of 
hypertrophic cartilage is a prerequisite step for the later ossification. There are several 
hypotheses as to why cartilage mineralisation did not occur in vitro. Either the culture 
conditions used were not conducive to cartilage mineralisation by the hypertrophic 
chondrocytes or that the interaction of another cell type, for example, endothelial or 
osteoblast progenitors, was required in order for initiation of the cartilage mineralisation 
stage.  
On in vivo subcutaneous implantation vascularisation of the tissue constructs occurred before 
subsequent mineralisation and bone formation was observed. Endothelial progenitors and 
haematopoietic stem cells which express CD34+ have previously been shown to be important 
for the neovascularisation of fractures and subsequent fracture healing [53]. Olmsted-Davis et 
al observed that CD34+ cells have the ability to generate osteogenic cells, which can express 
osteogenic markers, osteocalcin and alkaline phosphatase [54]. The decrease in ECM 
observed around the vascularisation of the graft can be attributed to the vascularisation of the 
hypertrophic cartilage. MMPs have been shown to be expressed by and around areas of 
vascularisation, including MMP-9 (gelatinase B) which has been shown to degrade collagens 
within the ECM of hypertrophic cartilage [55]. This need for the initial vascularisation of the 
tissue constructs highlights the importance of the expression of angiogenic factors, such as 
VEGF, within the grafts in order to recruit the CD34+ cells [11].  
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On implantation into a cranial bone defect, the nasal chondrocyte/PGA constructs were 
invaded by blood vessels and the cartilage was re-modelled into bone-like tissue. Although 
the size of bone defect used enabled self-healing given sufficient time; the bone defects 
containing the nasal chondrocyte/PGA constructs showed significantly more bone 
regeneration.   The bone regeneration observed within the hypertrophic cartilage grafts after 
in vivo implantation therefore may be a downstream reaction to the invasion of the tissue by 
blood vessels and the degradation of the hypertrophic cartilage matrix, as vascularisation 
allows for the influx of osteoblasts and monocyte-derived osteoclasts to regulate bone 
formation [12]. 
5. Conclusion 
There are relatively few studies looking at the potential of using hypertrohic cartilage as a 
potential method to produce a bone graft substitute and  most of this research is directed to 
using bone marrow derived MSCs to engineer cartilage constructs with hypertrophic cartilage 
features. This study shows that that adult nasal chondrocytes can be used to produce a tissue 
engineered hypertrophic cartilage-like tissue with morphological and phenotypical 
similarities to that of the hypertrophic cartilage found within a growth plate. Furthermore, 
this engineered hypertrophic cartilage can undergo vascularisation and enable subsequent 
bone formation once implanted in vivo,  in a bone defect. Within the 14 months there has 
been a single report showing that hypertrophic cartilage grafts formed from nasal 
chondrocytes (adult human nasal chondrocytes) could undergo endochondral ossification in a 
nude mouse (Pippenger et al, [30]). The use of nasal chondrocytes to produce a hypertrophic 
cartilage is an exciting progression in developmental engineering and further research into 
this area has potential to lead to the production of a new clinical bone graft substitute for 
bone grafting. 
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Supplementary Data  
 
Supplementary Figure 1: Representative immunohistochemical controls for 
immunolocalisation of collagen type II and collagen type X (scale bars 100 µm) 
 
 
Supplementary Figure 2:  Effect of 3D culture on the gene expression of chondrocytes 
relative to the expression profile observed in chondrocytes maintained in a 2D tissue culture 
environment. Collagen type II, collagen type X, alkaline phosphatase, Ihh, Sox9 and Runx2 
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expression within the chondrocytes were all assessed after the 72h scaffold seeding period 
(n=3, *p=0.05). 
 
Supplementary Figure 3: Histological and immunohistochemical images of tissue sections 
of the nasal chondrocyte/PGA constructs after 42 days in vitro culture and prior to 
subcutaneous implantation.  Images show the general tissue morphology (H&E stained 
section, a) collagen X deposition (b), alkaline phosphatase activity, ALP (c) and lack of 
mineralisation as detected by Alizarin Red staining (d). Scale bars =200 µm. 
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Supplementary Figure 4: Representative images of tissue sections showing 
immunolocalisation of CD45 (a) and CD68 (b) taken from nasal chondrocyte constructs 4 
weeks after subcutaneous implantation. The images indicate a moderate level of leucocyte 
(CD45+ve) and macrophage (CD68+ve) infiltration on the periphery of the construct, around 
blood vessels with little infiltration in the body of the tissue. 
Supplementary Figure 5: Representative images of tissue sections nasal chondrocyte/PGA 
constructs after 8 weeks in in vitro culture.  Images show the general tissue morphology 
(H&E stained section, a) collagen X deposition (b), alkaline phosphatase activity, ALP (c) 
and lack of mineralisation as detected by Alizarin Red staining (d). Scale bars= 200 µm. 
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Supplementary Figure 6: Histological and immunohistochemical images of tissue sections 
of the nasal chondrocyte/PGA constructs after 35 days in vitro culture and prior to 
implantation in a calvarial cranial defect.  The images show typical features of hypertrophic 
chondrocytes. The general tissue morphology showed increased cell volume [H&E stained 
section (a)] and proteoglycan deposition [purple coloured areas in Toluidine Blue-stained 
section (b) and light blue colour in Alcian Blue stained section (d)].The constructs also 
showed of collagen X deposition [brown stained areas, in image (e)]. The inset image in (e) 
shows the non-specific binding control. Alkaline phosphatase activity (ALP) was observed 
(black staining in image (d) and lack of mineralisation was observed as detected by Alizarin 
Red staining (f). Scale bars =200 µm. 
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Supplementary Figure 7: Representative images of tissue sections of the empty calvarial 
defects (no nasal chondrocyte-PGA hypertrophic construct implanted).The images show 
H&E stained sections taken from calvaria  4, 8 and 12 weeks after the defects were surgically 
created. Formation of a fibrous strand of tissue bridging the defects was observed with some 
bone regeneration occurring around the edge of the defect. However, no bone formation was 
seen towards the centre. (n=3 per time point). Scale bars= 500 µm. 
 
 
 
 
 
